On 6 November 2024, Regeneron and Sanofi announced that the EC, as recommended by CHMP, has approved Dupixent® (dupilumab) to treat eosinophilic esophagitis (EoE) in children aged 1 to 11 years who weigh at least 15 kg and who are inadequately controlled by, intolerant to, or who are not candidates for conventional medicinal therapy.
This expands the initial approval in the EU for EoE in adults and adolescents and makes Dupixent® the first medicine indicated to treat these young patients. Dupixent® is also approved in this age group in the US and Canada.